NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

Oncotarget

Volumn 6, Issue 8, 2015, Pages 5720-5734

  Mologni, Luca ^a   Ceccon, Monica ^a   Pirola, Alessandra ^a   Chiriano, Gianpaolo ^b   Piazza, Rocco ^a   Scapozza, Leonardo ^b   Gambacorti Passerini, Carlo ^a,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

ASP3026; Inhibitor; NPM ALK; PF 06463922; Resistance

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CERITINIB; CRIZOTINIB; NUCLEOPHOSMIN; PF 06463922; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; MACROCYCLIC LACTAM; NUCLEAR PROTEIN; P80(NPM-ALK) PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SULFONE; TRIAZINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IC50; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MOLECULAR MODEL; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETULUS; HUMANS; LACTAMS, MACROCYCLIC; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MODELS, MOLECULAR; MUTATION; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SULFONES; TRIAZINES;

EID: 84925645313     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3122     Document Type: Article

References (49)

1. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481:306-13.
2. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876-80. Epub 2001 Jun 21.
3. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012; 485:260-3.
4. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19:1401-9.
5. Mologni L. Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs. 2012; 21:985-94.
6. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011; 5:471-85.
7. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363:1734-9.
8. Doebele RC, Pilling AB, Aisner D, et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res. 2012; 18:1472-1482.
9. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70:10038-43.
10. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4:120ra17.
11. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71:6051-60.
12. Ceccon M, Mologni L, Bisson W, et al. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013; 11:122-32.
13. Ceccon M, Mologni L, Giudici G, et al. TREATMENT EFFICACY AND RESISTANCE MECHANISMS USING THE SECOND-GENERATION ALK INHIBITOR AP26113 IN HUMAN NPM-ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA. Mol Cancer Res. 2014; [Epub ahead of print].
14. Kuromitsu S, Mori M, Shimada I, et al. Anti-tumor activity of ASP3026, -A novel and selective ALK inhibitor Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 2011; 71:Abstract #2821.
15. Mori M, Kuromitsu S, Ueno Y, et al. ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012. Abstract nr. 866.
16. Mori M, Ueno Y, Konagai S, et al. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther. 2014; 13:329-40.
17. George SK, Vishwamitra D, Manshouri R, et al. The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget. 2014; 5:5750-63.
18. Maitland ML, Ignatius Ou SH, Tolcher AW, et al. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a "fast follower" phase 1 trial design. Journal of Clinical Oncology-ASCO Annual Meeting Proceedings. 2014; 32:suppl; abstr 2624.
19. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011; 19:679-90.
20. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370:1189-97.
21. Zhang S, Wang F, Keats J, et al. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 AACR Annual Meeting 2010. Poster # LB-298.
22. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(m etheno)pyrazolo[4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014; 57:4720-44.
23. Fontana D, Ceccon M, Gambacorti-Passerini C, et al. Activity of second-generation ALK inhibitors against crizotinib resistant mutants in NPM-ALK compared to EML4-ALK model. Cancer Medicine. 2015; in press.
24. Sun HY, Ji FQ. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. Biochem Biophys Res Commun. 2012; 423:319-24.
25. Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012; 87:E125-8.
26. Friboulet L, Li N, Katayama R, et al. The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer. Cancer Discov. 2014; 4:662-73.
27. Heuckmann JM, Holzel M, Sos ML, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res. 2011; 17:7394-401.
28. Bossi RT, Saccardo MB, Ardini E, et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry. 2010; 49:6813-25.
29. Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010; 430:425-37.
30. Shen L, Ji HF. More on crizotinib. N Engl J Med. 2011; 364:777-8.
31. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455:930-5.
32. Hemmer W, McGlone M, Tsigelny I, et al. Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase. J Biol Chem. 1997; 272:16946-54.
33. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003; 4:75-85.
34. Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. J Clin Oncol. 2013; 31:abstr 8031.
35. Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014; 106:djt378.
36. Katayama R, Friboulet L, Koike S, et al. Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. Clin Cancer Res. 2014; 20:5686-96.
37. Ou SH, Klempner SJ, Greenbowe JR, et al. Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. J Thorac Oncol. 2014; 9:1821-5.
38. Zdzalik D, Dymek B, Grygielewicz P, et al. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol. 2014; 140:589-98.
39. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011; 78:999-1005.
40. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455:967-70.
41. Bresler SC, Wood AC, Haglund EA, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011; 3108ra14.
42. Ignatius Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014; 9:549-53.
43. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2010; 29:e443-5.
44. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALKpositive patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2010; 28:18s(abstr 3).
45. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013; 14:590-8.
46. Yamazaki S, Lam JL, Zou HY, et al. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J Pharmacol Exp Ther. 2014; 351:67-76.
47. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89:1394-404.
48. Mologni L, Sala E, Cazzaniga S, et al. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006; 37:199-212.
49. SYBYL 7.3, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.